MedPacto (A235980) Stock Overview
Engages in the development and sale of marker-based new drugs in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
A235980 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
MedPacto, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩5,430.00 |
| 52 Week High | ₩8,650.00 |
| 52 Week Low | ₩2,750.00 |
| Beta | 0.51 |
| 1 Month Change | -10.98% |
| 3 Month Change | -21.19% |
| 1 Year Change | 48.16% |
| 3 Year Change | -70.71% |
| 5 Year Change | -93.86% |
| Change since IPO | -69.75% |
Recent News & Updates
Companies Like MedPacto (KOSDAQ:235980) Can Afford To Invest In Growth
Jan 30
MedPacto (KOSDAQ:235980) Is In A Strong Position To Grow Its Business
Oct 18Recent updates
Companies Like MedPacto (KOSDAQ:235980) Can Afford To Invest In Growth
Jan 30MedPacto (KOSDAQ:235980) Is In A Strong Position To Grow Its Business
Oct 18We're Not Worried About MedPacto's (KOSDAQ:235980) Cash Burn
Jul 05We Think MedPacto (KOSDAQ:235980) Can Afford To Drive Business Growth
Mar 22Companies Like MedPacto (KOSDAQ:235980) Are In A Position To Invest In Growth
Nov 18Companies Like MedPacto (KOSDAQ:235980) Are In A Position To Invest In Growth
Aug 05MedPacto (KOSDAQ:235980) Is In A Good Position To Deliver On Growth Plans
Mar 28We Think MedPacto (KOSDAQ:235980) Can Afford To Drive Business Growth
Jan 05Shareholder Returns
| A235980 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 6.7% | 1.1% | 0.3% |
| 1Y | 48.2% | 38.6% | 109.7% |
Return vs Industry: A235980 exceeded the KR Biotechs industry which returned 38.6% over the past year.
Return vs Market: A235980 underperformed the KR Market which returned 109.7% over the past year.
Price Volatility
| A235980 volatility | |
|---|---|
| A235980 Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in KR Market | 15.3% |
| 10% least volatile stocks in KR Market | 4.2% |
Stable Share Price: A235980 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A235980's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 56 | Seong-Jin Kim | www.medpacto.com |
MedPacto, Inc. engages in the development and sale of marker-based new drugs in South Korea. MedPacto, Inc. was established in 2013 and is based in Seoul, South Korea.
MedPacto, Inc. Fundamentals Summary
| A235980 fundamental statistics | |
|---|---|
| Market cap | ₩186.11b |
| Earnings (TTM) | -₩14.57b |
| Revenue (TTM) | ₩2.47b |
Is A235980 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A235980 income statement (TTM) | |
|---|---|
| Revenue | ₩2.47b |
| Cost of Revenue | ₩2.25b |
| Gross Profit | ₩220.06m |
| Other Expenses | ₩14.79b |
| Earnings | -₩14.57b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -425.11 |
| Gross Margin | 8.91% |
| Net Profit Margin | -590.14% |
| Debt/Equity Ratio | 0% |
How did A235980 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/13 22:26 |
| End of Day Share Price | 2026/03/13 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MedPacto, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Taehee Kim | Mirae Asset Securities Co., Ltd. |
| Eun Jung Song | Nomura Securities Co. Ltd. |